logo
Share SHARE
FONT-SIZE Plus   Neg

AVI BioPharma's Eteplirsen Meets PrimaryEndpoint For Duchenne Muscular Dystrophy

AVI BioPharma Inc. (AVII), a developer of RNA-based therapeutics, reported that treatment with eteplirsen met the primary efficacy endpoint in a randomized, double-blind, placebo-controlled Phase IIb study in boys with Duchenne muscular dystrophy or DMD. Eteplirsen administered once weekly at 30mg/kg over 24 weeks resulted in a statistically significant increase in novel dystrophin compared to no increase in the placebo group.

In the study, a shorter duration of eteplirsen treatment, 12 weeks, did not show a significant increase in novel dystrophin, despite administration of the drug at a higher dose, the company added. This finding suggests that a longer duration of dosing is required before meaningful levels of dystrophin are produced.

Eteplirsen is AVI's lead drug candidate that is systemically delivered for the treatment of a substantial subgroup of patients with DMD.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The best companies make employees feel comfortable, safe and valued at their workplace. Corporate culture develops organically over time from the cumulative traits of the people hired by the company. It is a combination of values, goals and vision of an organization that dictates the way people work.... Starbucks will close all its 379 Teavana stores over the coming year, with the coffee giant saying that the stores have been "persistently underperforming." The move will impact about 3,300 employees. The company made the announcement while reporting its third-quarter financial results on Thursday. Wal-Mart Stores has disappointed Nintendo fans after it cancelled pre-orders for the Super Nintendo Entertainment System - Classic Edition, a standalone mini Super Nintendo with pre-loaded games. The console is slated to be launched later this fall.
comments powered by Disqus
Follow RTT